upfront asct for newly diagnosed multiple myeloma: double vs. single transplant
Published 6 years ago • 133 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
0:59
defining the origins of multiple myeloma
-
1:38
selecting and sequencing therapies for r/r multiple myeloma
-
1:55
asct remains at the forefront of multiple myeloma therapy
-
3:44
is double autologous transplantation in multiple myeloma superior in the age of new agents?
-
2:30
a new era of treatment for multiple myeloma
-
1:29
the future of adcs in treating multiple myeloma
-
3:34
maintenance therapy following salvage asct for multiple myeloma
-
1:24:51
mds 2023: ps 2 - from clonal hematopoiesis to overt mds
-
29:21
haemostasis overview
-
6:23
how long will i live with multiple myeloma, and is there a cure? #myeloma
-
1:43
feasibility of double autologous stem cell transplantation in patients with al amyloidosis
-
3:28
the epigenetics of multiple myeloma and the rationale for hdac inhibitors
-
1:10
a trial investigating ibervd in transplant-ineligible newly diagnosed multiple myeloma
-
3:01
treatment approaches for asct-eligible myeloma patients in the frontline
-
2:17
moving towards fixed-duration treatment in multiple myeloma
-
1:04
the changing role of autosct in the treatment of multiple myeloma in the era of novel agents
-
1:53
the future of multiple myeloma treatment
-
2:39
a look into the future of multiple myeloma treatment: t-cell redirecting therapies vs autohsct
-
1:08
the impact of extramedullary multiple myeloma on outcomes with ide-cel
-
1:33
the role of allogeneic transplantation in patients with multiple myeloma
-
1:11
advances that have been made in the molecular characterization of multiple myeloma